Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20010018053 A1
Publication typeApplication
Application numberUS 09/774,770
Publication dateAug 30, 2001
Filing dateJan 31, 2001
Priority dateSep 14, 1999
Also published asCA2436403A1, EP1363666A1, EP1363666A4, US6294171, WO2002060481A1
Publication number09774770, 774770, US 2001/0018053 A1, US 2001/018053 A1, US 20010018053 A1, US 20010018053A1, US 2001018053 A1, US 2001018053A1, US-A1-20010018053, US-A1-2001018053, US2001/0018053A1, US2001/018053A1, US20010018053 A1, US20010018053A1, US2001018053 A1, US2001018053A1
InventorsJohn McMichael
Original AssigneeMcmichael John
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Methods for treating disease states comprising administration of low levels of antibodies
US 20010018053 A1
Abstract
The invention provides methods and compositions for treating the symptoms of disease states associated with the presence of a toxin or infectious agent having the step of administering an antibody specific for the toxin or infectious agent at a dosage of less than 0.1 mg per day.
Images(5)
Previous page
Next page
Claims(33)
What is claimed is:
1. A method of treating the symptoms of a disease state associated with the presence of a toxin or infectious agent comprising the step of administering an antibody specific for said toxin or infectious agent at a dosage of less than 0.1 mg per day.
2. The method of
claim 1
wherein the antibody is a monoclonal antibody.
3. The method of
claim 1
wherein the antibody is administered orally.
4. The method of
claim 3
wherein the antibody is administered by oral drench.
5. The method of
claim 3
wherein the antibody is administered sublingually.
6. The method of
claim 3
wherein the antibody is administered in an enterically protected form.
7. The method of
claim 1
wherein the antibody is administered by injection.
8. The method of
claim 7
wherein the antibody is administered by subcutaneous injection.
9. The method of
claim 1
wherein the disease state is autism and the method comprises administering an effective amount of anti-rubeola antibody.
10. The method of
claim 9
wherein the anti-rubeola antibody is administered at a dosage of from 610−7 to 810−5 per day.
11. The method of
claim 1
wherein the disease state is multiple sclerosis and the method comprises administering an effective amount of anti-rubeola antibody.
12. The method of
claim 11
wherein the anti-rubeola antibody is administered at a dosage of from 210−5 to 210−3 per day.
13. The method of
claim 1
wherein the disease state is selected from the group consisting of attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) and the method comprises administering an effective amount of anti-rubeola antibody.
14. The method of
claim 13
wherein the anti-rubeola antibody is administered at a dosage of from 110−5 to 110−4 per day.
15. The method of
claim 1
wherein the disease state is cancer and the method comprises administering an effective amount of anti-chorionic gonadotropin antibody.
16. The method of
claim 15
wherein the antibody is hCG.
17. The method of
claim 15
wherein the anti-chorionic gonadotropin antibody is administered as a dosage of from 110−5 to 110−4 per day.???
18. The method of
claim 15
wherein the cancer is a sarcoma.
19. The method of
claim 15
wherein the cancer is an osteosarcoma.
20. The method of
claim 1
wherein the disease state is pulmonary infection and the method comprises administering an effective amount of anti-Mycoplasma pneumonia antibody.
21. The method of
claim 20
wherein the anti-Mycoplasma pneumonia antibody is administered at a dosage of from 110−5 to 110−4 per day.
22. The method of
claim 1
wherein the disease state is Alzheimer's Disease and the method comprises administering an effective amount of anti-amyloid beta antibody.
23. The method of
claim 22
wherein the anti-amyloid-beta antibody is administered at a dosage of from 110−5 to 110−4 per day.
24. A method of treating the symptoms of diabetes comprising administering an effective amount of anti-glutamic acid decarboxylase antibody.
25. The method of
claim 24
wherein the anti-glutamic acid decarboxylase antibody is administered at a dosage of less than 0.1 mg per day.
26. The method of
claim 24
wherein the anti-glutamic acid antibody is administered at a dosage of from 110−5 to 110−4 per day.
27. A method of treating symptoms of Crohn's Disease comprising the step of administering an effective amount of anti-rubeola antibody.
28. The method of
claim 27
wherein the anti-rubeola antibody is administered at a dosage of less than 0.1 mg per day.
29. The method of
claim 27
wherein the anti-rubeola antibody is administered at a dosage of 110−5 to 110−4 per day.
30. A method of treating symptoms of rheumatoid arthritis comprising the step of administering an effective amount of anti-Klebsiella pneumonia antibody.
31. The method of
claim 30
wherein the anti-Klebsiella pneumonia antibody is administered at a dosage of less than 0.1 mg per day.
32. The method of
claim 30
wherein the anti-Klebsiella pneumonia antibody is administered at a dosage of from 110−4 to 110−3 per day.
33. A pharmaceutical composition for administration to a subject for treatment of a disease state comprising antibody specific for a toxin or infectious agent associated with the disease state in a dosage unit of less than 0.1 mg antibody.
Description
  • [0001]
    This application is a continuation-in-part of U.S. patent application Ser. No. 09/514,993 filed Feb. 29, 2000 and issued ______ as U.S. Pat. No. ______ which claims benefit of U.S. Provisional Patent Application Serial No. 60/153,838 filed Sep. 14, 1999 the disclosures of which are hereby incorporated by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    The therapeutic use of antibodies is generally limited to: (a) immunotherapy where a specific antibody directed against a discreet antigen is used to counter the effect of that antigen. Examples include using an antitoxin administered to neutralize a toxin, or antibody against an infectious agent to interrupt the pathophysiological process induced by that target organism; (b) the administration, often iv, of high levels of antibody (gamma globulin therapy) to compensate for transient or permanent immune deficiency; and (c) monoclonal antibody therapy to combat cancer, certain autoimmune disorders and metabolic diseases. In all these cases, antibody is provided in relatively high concentrations for the purpose of having that antibody combine directly with its target antigen to render that antigen inoperable, non-infectious or neutralized. For example, Gamimune™ (Bayer Biological) contains 50 mg protein (immunoglobin) per mL and normal dosing can be up to 1000 mg/kg body weight. Gammar -P™ I.V. (Aventis Behring) is administered at dosages up to 400 mg/kg body weight. Bayhep B™ (Hepatitis B Immunoglobulin) (Bayer Biological) is 15-18% protein [immunoglobulin] is administered at dosages of up to 0.6 ml/kg body weight=0.01 g/kg=100 mg/kg. Further, Imogam Rabies—HT™ (Aventis Pasteur) is 10-18% protein, and is administered at a dosage of 0.133 ml/kg (240 mg/kg) body weight.
  • [0003]
    Of interest to the present application is the disclosure of co-owned, allowed U.S. patent application Ser. No. 09/514,993 which is directed to the administration of anti-rubeola antibodies for the treatment of symptoms of various central nervous system diseases including autism, multiple sclerosis, attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Examples therein demonstrated the efficacy of treating the symptoms of those disease states with dosages of from 0.1 mg to 1 mg of anti-rubeola antibody per dose.
  • [0004]
    While the administration of larger quantities of immunoglobulins is effective in the treatment of many disease states there remains a desire in the art for alternative methods for treatment of disease states.
  • SUMMARY OF THE INVENTION
  • [0005]
    The present invention is directed to the discovery that the symptoms of disease states associated with the presence of a toxin or infectious agent may be effectively treated by administration of very low levels of antibodies specific for the toxin or infectious agent. The levels of antibodies administered are substantially lower than those traditionally administered to directly neutralize target antigens and for example are typically less than 0.1 mg of antibody per day. Specifically, the antibodies may be administered in one or in multiple dosages but the sum of antibodies administered in any 24 hour period is less than 0.1 mg.
  • [0006]
    While the antibody may be monoclonal or polyclonal, it is preferably monoclonal according to one aspect of the invention. The antibody may be administered by a variety of manners but is preferably administered enterically and most preferably orally. Suitable methods of oral administration include oral drench and sublingual administration. According to another preferred aspect of the invention the antibody is administered in an enterically protected form. In addition, the antibodies of the invention may be administered by injection such as by subcutaneous injection.
  • [0007]
    The symptoms of various disease states can be treated according to the invention including those of various central nervous disorders including autism, multiple sclerosis, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD), all of which can be treated by administration of very low levels of anti-rubeola antibody. Dosages of antibodies administered according to the invention including anti-rubeola antibodies range from 110−10 to a 110−1 mg/dosage with dosages of from 110−5 to 110−4 mg (e.g. 810−5 mg) and dosages of from 210−5 to 2103 mg being preferred.
  • [0008]
    The invention also provides treatment of the symptoms of pulmonary infection by administering an effective amount of anti-Mycoplasma pneumonia antibody with daily dosages of less than 0.1 mg being preferred and daily dosages ranging from 110−5 to 110−3 mg/day being particularly preferred.
  • [0009]
    The invention also provides treatment of symptoms of Alzheimer's Disease by administering an effective amount of anti-amyloid beta antibodies with daily dosages of less than 0.1 mg being preferred and daily dosages ranging from 110−5 to 110−3 mg/day being particularly preferred.
  • [0010]
    According to a further aspect of the invention it has been discovered that administration of anti-rubeola antibodies can be effective in the treatment of symptoms of Crohn's Disease. Accordingly, the invention provides a method of treating the symptoms of Crohn's Disease comprising administering an effective amount of anti-rubeola antibody. Preferred dosages are less than 0.1 mg antibody daily with daily dosages ranging from 210−5 to 210−3 mg being particularly preferred.
  • [0011]
    According to a further aspect of the invention it has been discovered that the administration of anti-Klebsiella pneumonia antibodies can be useful for the treatment of rheumatoid arthritis and specifically for juvenile rheumatoid arthritis. Preferred dosages are less than 0.1 mg of anti-Klebsiella pneumonia antibody daily with daily dosages ranging from 110−4 to 110−3 mg/day (e.g. 410−4 mg/day) being particularly preferred.
  • [0012]
    The invention also provides methods for treating the symptoms of diabetes comprising the method of administering an effective amount of antibody directed against glutamic acid decarboxylase. Preferred dosages are less than 0.1 mg of anti-glutamic acid decarboxylase antibody daily with daily dosages ranging from 110−4 to 110−3 mg/day (e.g. 410−4 mg/day) being particularly preferred.
  • [0013]
    The invention also provides pharmaceutical compositions for administration to subjects for treatment of the symptoms of disease states comprising antibody specific for a toxin or infectious agent associated with the disease state in a dosage unit of less than 0.1 mg antibody.
  • DETAILED DESCRIPTION
  • [0014]
    Without intending to be bound by any particular theory of the invention, it is believed that the invention described herein utilizes antibodies in remarkably low concentrations as molecular signals to induce a response similar or even superior to that seen with the traditional approach of introducing antibody at concentrations several logs greater than that associated with this invention. However, even though the concentrations of antibody are significantly different between traditional use and this invention, the specificity of the reaction remains intact. That is, low level of antibody directed against target A will react with target A but not B, unless B is antigenically closely related to A.
  • [0015]
    The similarity in responses between traditional gammaglobulin therapy and the invention, and the disparity of concentrations of antibody to induce the desired result, recalls the relationship in concentrations of antigen, or antigenic extract, used by allergists employing the maximum tolerated dose approach to hypersensitivity therapy and those using the neutralization method.
  • [0016]
    In the case of the present invention results similar to those obtained by traditional gamma globulin therapy are reached by an apparently different pathway. The traditional approach of using specific antibody in high concentration to treat or counter a specific antigen is well understood in that the antibody makes direct contact with its antigen target, combines with it, and alone or in the presence of other factors, such as the complement system, the antigen is destroyed or neutralized. The mechanism of action of the present invention whereby antigens are destroyed or neutralized by a pathway initiated by the presence of low levels of antibodies specific for the antigen is not completely understood but is the focus of ongoing research.
  • [0017]
    The invention described herein provides methods for treating ADD/ADHD, autism, MS, Crohn's Disease and related disorders. The invention describes the use of specific anti-rubeola antibody used a relatively low dose as a systemic signal to specifically inhibit virus replication or the body's aberrant response to the virus that results in the symptoms characteristic of the diseases.
  • [0018]
    Anti-rubeola antibody useful in practice of the invention may be obtained from a variety of sources. Suitable antibodies may be polyclonal or monoclonal and can be derived from various animal sources. A preferred anti-rubeola antibody for use in practice of the invention is polyvalent rabbit anti-rubeola antibody available from Cortex Biochemicals, San Leandro, Calif.
  • [0019]
    Antibodies specific for other antigens such as Klebsiella pneumonia, Mycoplasma pneumonia, chorionic gonadotropins, Amyloid-beta, and glutamic acid decarboxylase may be obtained from various commercial sources. A preferred source of antibody for Klebsiella pneumonia is Bio-Trend Chemikalien, Cologne, Germany and preferred anti-Mycoplasma pneumonia antibodies may be obtained from Cortex Biochemicals, San Leandro, Calif. Preferred sources of anti-amyloid-beta antibodies are Chemicon International Inc., Temecula, Calif. and Boeringer Mannheim with preferred antibodies being those directed against human chorionic gonadotropin (hCG) holoprotein. A preferred antibody specific for glutamic acid decarboxylase is available from Chemicon International Inc., Temecula, Calif.
  • [0020]
    The following examples are illustrative and are not intended to limit either the scope or spirit of the invention.
  • EXAMPLES Example I
  • [0021]
    According to this example, low dosages of anti-rubeola antibody were administered to an eight year old male subject exhibiting the symptoms of attention deficit disorder. Specifically, the subject was treated by sublingual administration once daily of one drop of a composition comprising 810−5 mg of anti-rubeola antibody (Cortex Biochemicals, San Leandro, Calif.). The subject exhibited improvements in concentration and improved grades with some increase in activity in the evenings.
  • Example II
  • [0022]
    According to this example, a female subject in her mid-thirties presented with a 12 year history of multiple sclerosis which primarily affected muscle control of her legs. The subject was treated by sublingual administration twice daily of one drop of a composition comprising 810−5 mg of anti-rubeola antibody (Cortex Biochemicals, San Leandro, Calif.). After a period of three weeks, the subject exhibited improved motor control and was capable of driving an automobile for the first time in years.
  • Example III
  • [0023]
    According to this example, four dogs presenting with progressive central nervous system pathology and exhibiting symptoms similar to those of multiple sclerosis were treated by administration of 810−5 mg per day dosages of anti-rubeola antibodies by subcutaneous injection. The animals were treated over a period of eight months and were either stable or slowly improving with respect to their condition.
  • Example IV
  • [0024]
    According to this example, human patients presenting with cancer of various types (pancreatic, lung and colon) are treated by two to four times daily sublingual administration of 810−5 mg polyclonal anti-hCG antibodies derived from rabbits (Cortex Biochemicals, San Leandro, Calif.)
  • Example V
  • [0025]
    According to this example, four dogs suffering with osteosarcoma were treated by subcutaneous injection of 3.210−5 mg per day of anti-hCG antibody. Canine osteosarcoma usually metastisizes from the bone to the lungs and animals similarly afflicted typically have a lifespan of six-months. After five months of treatment the dogs do not exhibit signs of metastisis and appear in healthy condition as evidenced by coat condition, appetite, attitude and quality of life.
  • Example VI
  • [0026]
    According to this example two patients aged 8 and 9 presented with severe juvenile rheumatoid arthritis and were treated by sublingual administration twice daily of 810−5 mg of antibodies specific for Klebsiella pneumonia obtained from Bio-Trend Chemikalien, Cologne, Germany. Prior to being treated the subjects suffered from pain, restricted range of motion, and joints which were swollen and sore. After one week of treatment according to the methods of the invention, pain and swelling were reduced and the range of movement was increased. Optimum concentration of antibody per dose has been approximately 410−4 mg.
  • Example VII
  • [0027]
    According to this example, a patient presented with chronic pulmonary infections and fibrosis exhibiting symptoms of shortness or breath, chest pain and decreased stamina. The subject was treated by sublingual administration twice daily of 810−5 mg of antibody to Mycoplasma pneumonia (Biochemicals, San Leandro, Calif.). The subject reported a positive response within 7 days, as evidenced by decreased shortness of breath, decreased chest pain, decreased edema, increased stamina and ability to carry out normal activities of daily living.
  • Example VIII
  • [0028]
    According to this example, five patients presented with the symptoms of Alzheimer's disease and were treated by sublingual administration of four drops daily of a composition comprising 510−6 mg of anti-amyloid beta antibodies (Boeringer Mannheim). At four weeks after treatment, three of the patients did not exhibit any effects but one patient reported having an improved pattern of speech as words came easier to her. The fifth subject reported that after two weeks she was no longer “struggling to remember things.”
  • Example IX
  • [0029]
    According to this example five senile dogs were treated by subcutaneous administration with 510−6 mg of anti-amyloid beta antibodies. All the dogs responded positively after two weeks of daily treatment and were more active and interacted more appropriately with their masters.
  • [0030]
    Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the presently preferred embodiments thereof. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6710226Nov 27, 2000Mar 23, 2004Neuralab LimitedTransgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6743427Nov 28, 2000Jun 1, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6750324Nov 28, 2000Jun 15, 2004Neuralab LimitedHumanized and chimeric N-terminal amyloid beta-antibodies
US6761888May 26, 2000Jul 13, 2004Neuralab LimitedPassive immunization treatment of Alzheimer's disease
US6787138Nov 28, 2000Sep 7, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6787139Nov 28, 2000Sep 7, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6787140Nov 28, 2000Sep 7, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6787143Nov 28, 2000Sep 7, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6787144Nov 28, 2000Sep 7, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6787523Nov 30, 1998Sep 7, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6787637Nov 28, 2000Sep 7, 2004Neuralab LimitedN-Terminal amyloid-β antibodies
US6808712Mar 31, 2004Oct 26, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6818218 *Mar 31, 2004Nov 16, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6866849Mar 31, 2004Mar 15, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6866850Mar 31, 2004Mar 15, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6875434Nov 28, 2000Apr 5, 2005Neuralab LimitedMethods of treatment of Alzheimer's disease
US6890535Nov 28, 2000May 10, 2005Neuralab LimitedPharmaceutical compositions and methods for treatment of amyloid diseases
US6905686Nov 28, 2000Jun 14, 2005Neuralab LimitedActive immunization for treatment of alzheimer's disease
US6913745Jun 1, 2000Jul 5, 2005Neuralab LimitedPassive immunization of Alzheimer's disease
US6923964Jun 1, 2000Aug 2, 2005Neuralab LimitedActive immunization of AScr for prion disorders
US6936246Nov 28, 2000Aug 30, 2005Neuralab LimitedPassive immunization of ASCR for prion disorders
US6946135Sep 2, 2004Sep 20, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6962707Jul 1, 2004Nov 8, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6972127Sep 2, 2004Dec 6, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US6982084Mar 31, 2004Jan 3, 2006Neuralab LimitedPrevention and treatment of amyloidogenic disease
US7014855Mar 31, 2004Mar 21, 2006Neuralab LimitedPrevention and treatment of amyloidogenic disease
US7700751Feb 16, 2007Apr 20, 2010Janssen Alzheimer ImmunotherapyHumanized antibodies that recognize β-amyloid peptide
US7763250Apr 28, 2006Jul 27, 2010Rinat Neuroscience Corp.Antibodies directed against amyloid-beta peptide and nucleic acids encoding same
US7790856Sep 12, 2006Sep 7, 2010Janssen Alzheimer ImmunotherapyHumanized antibodies that recognize beta amyloid peptide
US7807165Aug 1, 2005Oct 5, 2010Rinat Neuroscience Corp.Antibodies directed against amyloid-beta peptide and methods using same
US7871615Jun 1, 2004Jan 18, 2011Janssen Alzheimer ImmunotherapyHumanized antibodies that recognize beta amyloid peptide
US7893214Aug 20, 2007Feb 22, 2011Janssen Alzheimer ImmunotherapyHumanized antibodies that recognize beta amyloid peptide
US7927594Aug 1, 2005Apr 19, 2011Rinat Neuroscience Corp.Antibodies directed against amyloid-beta peptide
US7964192May 28, 1999Jun 21, 2011Janssen Alzheimer ImmunotherapyPrevention and treatment of amyloidgenic disease
US7977316Aug 20, 2007Jul 12, 2011Elan Pharmaceuticals, Inc.Prevention and treatment of amyloidogenic diseases
US8003097Aug 23, 2011Janssen Alzheimer ImmunotherapyTreatment of cerebral amyloid angiopathy
US8034339Aug 20, 2004Oct 11, 2011Janssen Alzheimer ImmunotherapyPrevention and treatment of amyloidogenic disease
US8034348Aug 20, 2007Oct 11, 2011Janssen Alzheimer ImmunotherapyPrevention and treatment of amyloidogenic disease
US8105594Jan 25, 2010Jan 31, 2012Alan SolomonMethods for amyloid removal using anti-amyloid antibodies
US8124081Aug 20, 2007Feb 28, 2012Crimagua LimitedPrevention and treatment of amyloidogenic diseases
US8128928Aug 13, 2007Mar 6, 2012Wyeth LlcHumanized antibodies that recognize beta amyloid peptide
US8268593Apr 5, 2010Sep 18, 2012Rinat Neuroscience Corp.Polynucleotides encoding antibodies directed against amyloid-beta peptide
US8398978Mar 15, 2010Mar 19, 2013Rinat Neuroscience Corp.Antibodies directed against amyloid-beta peptide and methods using same
US8535673Aug 20, 2004Sep 17, 2013Janssen Alzheimer ImmunotherapyPrevention and treatment of amyloidogenic disease
US8613920Jul 27, 2007Dec 24, 2013Janssen Alzheimer ImmunotherapyTreatment of amyloidogenic diseases
US8642044Aug 20, 2007Feb 4, 2014Janssen Alzheimer ImmunotherapyPrevention and treatment of amyloidogenic disease
US8784810Oct 17, 2008Jul 22, 2014Janssen Alzheimer ImmunotherapyTreatment of amyloidogenic diseases
US8916165Dec 15, 2005Dec 23, 2014Janssen Alzheimer ImmunotherapyHumanized Aβ antibodies for use in improving cognition
US9051363Aug 20, 2007Jun 9, 2015Janssen Sciences Ireland UcHumanized antibodies that recognize beta amyloid peptide
US9067981Oct 29, 2009Jun 30, 2015Janssen Sciences Ireland UcHybrid amyloid-beta antibodies
US20030165496 *Dec 6, 2001Sep 4, 2003Elan Pharmaceuticals, Inc.Humanized antibodies that recognize beta amyloid peptide
US20040040658 *Aug 29, 2002Mar 4, 2004Tatehito UsuiSemiconductor fabricating apparatus and method and apparatus for determining state of semiconductor fabricating process
US20040082762 *Mar 12, 2003Apr 29, 2004Elan Pharmaceuticals, Inc.Humanized antibodies that recognize beta amyloid peptide
US20040087777 *Mar 12, 2003May 6, 2004Elan Pharmaceuticals, Inc.Humanized antibodies that recognize beta amyloid peptide
US20040146512 *Oct 9, 2003Jul 29, 2004Arnon RosenthalMethods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040166119 *Mar 31, 2004Aug 26, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20040171815 *Nov 7, 2003Sep 2, 2004Schenk Dale B.Humanized antibodies that recognize beta amyloid peptide
US20040171816 *Nov 7, 2003Sep 2, 2004Schenk Dale B.Humanized antibodies that recognize beta amyloid peptide
US20040175394 *Mar 31, 2004Sep 9, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20040228865 *Mar 31, 2004Nov 18, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20040247590 *Jul 13, 2004Dec 9, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20040247591 *Jul 12, 2004Dec 9, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20040265301 *Jul 12, 2004Dec 30, 2004Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050019343 *Sep 2, 2004Jan 27, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050031629 *Mar 31, 2004Feb 10, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050037026 *Sep 2, 2004Feb 17, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050123544 *Jul 12, 2004Jun 9, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050142132 *Feb 14, 2005Jun 30, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050158304 *Jul 12, 2004Jul 21, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050163788 *Sep 2, 2004Jul 28, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050191292 *Aug 20, 2004Sep 1, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050191314 *Apr 15, 2005Sep 1, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20050196399 *Aug 27, 2004Sep 8, 2005Schenk Dale B.Prevention and treatment of amyloidogenic disease
US20050249725 *Feb 27, 2004Nov 10, 2005Schenk Dale BHumanized antibodies that recognize beta amyloid peptide
US20050255122 *Sep 2, 2004Nov 17, 2005Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20060057701 *Aug 1, 2005Mar 16, 2006Arnon RosenthalAntibodies directed against amyloid-beta peptide and methods using same
US20060057702 *Aug 1, 2005Mar 16, 2006Arnon RosenthalAntibodies directed against amyloid-beta peptide and methods using same
US20060121038 *Jul 12, 2004Jun 8, 2006Neuralab LimitedPrevention and treatment of amyloidogenic disease
US20060280743 *Apr 28, 2006Dec 14, 2006Neuralab LimitedHumanized antibodies that recognize beta amyloid peptide
US20060292152 *Apr 28, 2006Dec 28, 2006Arnon RosenthalAntibodies directed against amyloid-beta peptide and methods using same
US20070160616 *Jan 12, 2007Jul 12, 2007Arnon RosenthalMethods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20070254314 *Oct 30, 2006Nov 1, 2007Geier Mark RMethods of treating autism and autism spectrum disorders
US20080248023 *Aug 20, 2007Oct 9, 2008Schenk Dale BPrevention and treatment of amyloidogenic diseases
US20080248029 *Aug 20, 2007Oct 9, 2008Schenk Dale BPrevention and treatment of amyloidogenic diseases
US20090285809 *Mar 30, 2009Nov 19, 2009Elan Pharmaceuticals, Inc.Prevention and treatment of amyloidogenic diseases
US20090285822 *Nov 19, 2009Elan Pharmaceuticals, Inc.Prevention and treatment of amyloidogenic disease
US20100322932 *Jan 25, 2010Dec 23, 2010Alan SolomonMethods for amyloid removal using anti-amyloid antibodies
US20110008834 *Apr 5, 2010Jan 13, 2011Rinat Neuroscience Corp.Polynucleotides encoding antibodies directed against amyloid-beta peptide
US20110064734 *Nov 5, 2010Mar 17, 2011Elan Pharmaceuticals, Inc.Prevention and treatment of amyloidogenic disease
US20110177066 *Jul 21, 2011Elan Pharma International LimitedPrevention and treatment of amyloidogenic diseases
US20110182893 *Jul 28, 2011Elan Pharma International LimitedPrevention and treatment of amyloidogenic diseases
Classifications
U.S. Classification424/159.1, 424/600
International ClassificationA61K39/00, A61P37/08, A61K9/08, A61P35/00, A61K39/07, A61K39/295, A61K9/20, A61P25/22, A61K9/48, A61P25/00, A61P11/00, C07K16/10, A61K39/395, C07K16/26, A61P25/14, C07K16/40, A61P25/28
Cooperative ClassificationC07K16/26, C07K16/1027, A61K2039/505, A61K39/3955, C07K16/40
European ClassificationA61K39/395C2, C07K16/40, C07K16/26, C07K16/10F
Legal Events
DateCodeEventDescription
Apr 12, 2001ASAssignment
May 28, 2002CCCertificate of correction
Mar 15, 2005FPAYFee payment
Year of fee payment: 4
Feb 25, 2009FPAYFee payment
Year of fee payment: 8
Feb 27, 2013FPAYFee payment
Year of fee payment: 12